Heron Therapeutics, Inc. (HRTX)
Makes medicines that deliver drugs slowly over days or weeks to prevent nausea from cancer treatment.
$0.49+0.06%Healthcare
StockGlow Score
Leaning Bearish
BearishBullish
1 year ago-71.2%
The outlook
HRTX is trading near its 52-week lows, well below both its 50- and 200-day moving averages. Analyst sentiment leans bearish overall, though the average price target sits about 312% above the current price, suggesting a wide gap between current valuation and what some analysts envision. The stock remains thinly valued with substantial upside implied in targets, but current momentum and positioning reflect caution.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range7% of the way from its 52-week low to high
Price targetAvg target +312% vs current price
Market cap
$92.0M
52-wk high
$1.90
52-wk low
$0.38
50-day avg
$0.53
200-day avg
$1.00
Trailing P/E
—